Medrol A (Methylprednisolone)

Methylprednisolone is a glucocorticoid that modulates inflammatory and immune pathways across several disease families.

• Inflammatory disorders: reduces inflammation and associated pain.
• Allergic reactions: mitigates severe hypersensitivity symptoms.
• Autoimmune diseases: suppresses aberrant immune activity.
• Asthma: decreases airway inflammation and improves breathing.
• Rheumatoid arthritis: alleviates joint swelling and damage.

• Methylprednisolone binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and alters gene transcription. This action suppresses the production of pro‑inflammatory cytokines, chemokines, and adhesion molecules while enhancing anti‑inflammatory protein expression, resulting in reduced inflammation and immune activation.

Methylprednisolone may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Increased appetite and weight gain.
• Insomnia or mood changes.
• Elevated blood glucose levels.
• Gastrointestinal discomfort or ulcer risk.
• Fluid retention and mild hypertension.
• Skin thinning or easy bruising.

Serious or Rare Side Effects

• Adrenal insufficiency on abrupt discontinuation.
• Severe infections due to immunosuppression.
• Osteoporosis and increased fracture risk.
• Cataracts or glaucoma.
• Psychosis or severe mood disorders.
• Anaphylaxis or severe allergic reaction.

Before initiating therapy, consider the following safety measures.

• Infection risk assessment: evaluate for active infections before use.
• Blood glucose monitoring: patients with diabetes may need dose adjustments.
• Bone health evaluation: long‑term use may require calcium/vitamin D supplementation.
• Tapering plan: avoid abrupt cessation to prevent adrenal crisis.
• Dose minimization: use the lowest effective dose for the shortest duration.
• Store at room temperature: keep in the original pack, protect from moisture.

Methylprednisolone can affect, or be affected by, several other medicines.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase steroid levels.
• Live vaccines: heightened risk of infection.
• Anticoagulants (e.g., warfarin): may enhance bleeding tendency.
• NSAIDs: increase gastrointestinal ulcer risk.
• Diuretics: may exacerbate hypokalemia.

Moderate Interactions (Monitor Closely)

• Antidiabetic agents: may require dose reduction due to hyperglycemia.
• Antihypertensives: steroid may blunt blood‑pressure control.
• Non‑live vaccines: monitor immune response.
• CYP3A4 inducers (e.g., rifampin): may reduce steroid efficacy.
• Antifungal azoles (e.g., fluconazole): may modestly raise steroid exposure.